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Highlights 
 TAT expression and prior METH exposure improved visual discrimination learning. 
 TAT and METH exposure impaired cognitive flexibility during reversal learning. 
 TAT expression improved early, but impaired late phase reversal learning. 
 Dopamine transporter levels in the caudate putamen were increased by TAT expression. 
 
ABSTRACT 
Mild neurocognitive impairments are common in people with human immunodeficiency virus 
(HIV) infection. HIV-encoded proteins, such as trans-activator of transcription (TAT), contribute to 
neuropathology and cognitive function in medicated subjects. The combination of TAT and 
comorbid methamphetamine use may further impair neurocognitive function in HIV-positive 
individuals by affecting dopaminergic systems in the brain. The current study examined the effects 
of TAT protein expression and methamphetamine exposure on cognitive function and dopamine 
systems in mice.  Transgenic mice with inducible brain expression of the TAT protein were exposed 
to a binge methamphetamine regimen. TAT expression was induced via a doxycycline-containing 
diet during the final stage of the regimen and maintained throughout cognitive testing. Learning and 
executive function were assessed using an operant visual discrimination protocol, with a strategy 
switch and reversal. TAT expression and methamphetamine exposure improved visual 
discrimination learning. Combined TAT expression and methamphetamine exposure increased 
perseverative errors during reversal learning. TAT expression altered reversal learning by 
improving early stage, but impairing late stage, learning. TAT expression was also associated with 
an increase in dopamine transporter expression in the caudate putamen. These results highlight that 
TAT expression and methamphetamine exposure likely affect a range of selective cognitive 
processes, with some potentially improving function under certain conditions. 
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Keywords: dopamine transporter; methamphetamine binge; reversal learning; perseveration. 
Abbreviations: human immunodeficiency virus (HIV), trans-activator of transcription (TAT), HIV-
associated neurocognitive disorders (HAND), dopamine transporter (DAT), continuous 
reinforcement (CRF), phosphate-buffered saline (PBS), analysis of variance (ANOVA), 
methamphetamine (METH).  
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1. Introduction  
Mild neurocognitive impairments are common in people with human immunodeficiency virus 
(HIV; over 35%), even those undergoing combination antiretroviral therapy [1]. HIV-associated 
neurocognitive disorders (HAND) include impairments in learning, executive functions and 
working memory [2, 3]. Underlying corticostriatal dysfunction, such HIV-induced decreases in 
caudate/basal ganglia volume [4, 5] and dopamine levels [6], may be associated with poorer 
cognitive performance [5, 7]. HIV-encoded proteins, such as trans-activator of transcription (TAT) 
and glycoprotein (gp) 120, contribute to neuronal dysfunction in the basal ganglia [8] and may 
explain the presence of cognitive impairments in subjects with low viral loads. For example, 
expression of gp120 in mice recapitulates learning deficits observed in  HIV-positive humans [9].   
Transgenic mice with inducible brain expression of the TAT protein [10] represent a powerful 
animal model to investigate the specific effects of TAT protein expression on cognitive function. 
Induction of the TAT protein results in neuropathology similar to that observed in HIV-infected 
humans [10] and leads to dysfunction in corticostriatal dopaminergic neurotransmission [11-17]. 
TAT exposure also induces a complex combination of cognitive dysfunction in rodents. For 
example, TAT impairs spatial learning [18, 19] but improves spatial reversal learning [12]. TAT 
expression also affects aspects of sensory motor gating [20]. However, TAT expression does not 
recapitulate the cognitive consequences of HIV disease entirely. For example, TAT expression does 
not impair delay-dependent working memory [13], even though working memory deficits are 
common in HIV [2, 3]. This combined evidence suggests that subcortical dopamine systems are 
particularly sensitive to neuropathology induced by HIV-associated proteins and this is associated 
with impairment of specific cognitive domains.  
Corticostriatal systems are also highly susceptible to methamphetamine-induced neurotoxicity 
[21, 22], which is a common comorbidity in HIV-infected subjects [23]. Comorbid 
methamphetamine use has been associated with increased neurocognitive impairments in HIV-
infected individuals [24, 25]. Furthermore, individuals who are both methamphetamine-dependent 
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and HIV-infected show exacerbated neuronal injury [26] and cortical interneuron loss [27, 28]. The 
susceptibility of corticostriatal dopaminergic systems to methamphetamine and the TAT protein, 
suggest their combined exposure may lead to further dysfunction. We have previously shown that 
TAT expression increases the sensitivity to methamphetamine reward [13] and enhances 
methamphetamine-induced sensitization [14]. However, their combined influence on cognitive 
function is understood less. 
The aim of the present study was to determine the combined effects of TAT protein expression 
and methamphetamine exposure on cognitive function in mice. To effectively model 
methamphetamine use and TAT expression in human subjects, we combined the temporal control of 
TAT expression in inducible transgenic mice [10] with a binge regimen of methamphetamine 
exposure that closely resembles use in human subjects [22]. Subsequent to methamphetamine 
exposure, learning and executive function were assessed using an operant visual discrimination 
protocol. This protocol featured the acquisition of a visual discrimination rule as a measure of 
learning, followed by strategy switch and reversal stages to assess executive function. To assess the 
effects of TAT and methamphetamine on brain dopaminergic systems, dopamine transporter (DAT) 
levels were determined in mesolimbic and striatonigral brain areas. 
 
2. Methods 
2.1 Animals 
A total of 48 male mice (9-14 months old at the beginning of the experiment) were provided by 
the Neuroscience and Animal Models Core of the Translational Methamphetamine AIDS Research 
Center (TMARC) and tested. Of these, 22 mice contained the GFAP promotor-controlled Tet-
binding protein (TAT-) and 26 contained both the GFAP promotor-controlled Tet-binding protein 
and the TRE promotor-TAT protein transgene (TAT+). There were no significant differences in 
ages between the test groups (TAT-/saline, 12.6 ± 0.3 [SEM]; TAT+/saline, 12.4 ± 0.4; TAT-
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/methamphetamine, 12.6 ± 0.5; TAT+/methamphetamine, 12.9 ± 0.4). Inducible TAT transgenic 
mouse colonies with a C57BL/6J background were obtained by generation of two separate 
transgenic lines Teton-GFAP mice and TRE-Tat86 mice, and then cross-breeding of these two 
transgenic mouse lines, as previously described [10]. The mice were housed 1-4 mice per cage in a 
humidity- and temperature-controlled animal facility on a 12 h/12 h reverse light/dark cycle (lights 
off at 7:00 AM).  Mice had ad libitum access to food and water during exposure to 
methamphetamine binge (1-3 weeks). As doxycycline has been shown to induce behavioral changes 
when administered to control mice [13], all mice were given a doxycycline-containing diet (6 g/kg 
diet #F4096, Bioserv Flemington, NJ). Mice were provided with the diet on day 21 of 
methamphetamine exposure (i.e., two days prior to cycle 4 of administration) and continuing 
throughout the experiment (see Table 1). Inducing TAT expression via chronic exposure to a 
doxycycline-containing diet has been demonstrated to produce functional changes to synaptic 
physiology and alterations in behavior [29]. During behavioral training and testing, mice were food 
deprived to 85% free-feeding weight, but had ad libitum access to water. Behavioral testing was 
conducted 7 days/week during the dark phase of the light/dark cycle from 2 pm to 7 pm with mice 
from all groups being tested concurrently at any given time throughout the testing period. All of the 
experiments were conducted in accordance with the guidelines of the American Association for the 
Accreditation of Laboratory Animal Care and National Research Council’s Guide for the Care and 
Use of Laboratory Animals and approved by the University of California San Diego Institutional 
Animal Care and Use Committee. 
 
2.2 Experimental Design 
Mice underwent the binge methamphetamine regimen and were placed on a doxycycline 
containing diet two days prior to the final cycle of the regimen. Mice remained on this diet for all 
subsequent behavioral testing. Visual discrimination training began two weeks after completion of 
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the binge regimen. The advanced age of the mice tested led to approximately 30% of the mice 
failing to reach criteria independent of TAT expression and methamphetamine exposure. This may 
also be a consequence of doxycycline administration. We have previously observed behavioral 
changes as a direct result of doxycycline administration in TAT- mice [13], which is why 
doxycycline treated TAT- mice were used as controls in the present study. An equivalent control 
group fed a diet without doxycycline would be required to establish age-dependent versus 
doxycycline-dependent effects on task completion. Thus, final group numbers for behavioral data 
were: TAT-/saline = 7, TAT+/saline = 9, TAT-/methamphetamine = 9, and 
TAT+/methamphetamine = 7. After completion of behavioral testing, mice underwent anaesthetized 
magnetic resonance imaging (these data are not presented in this manuscript) and then brain 
samples from all mice (15-20 months old) were collected for immunohistochemistry analyses 
(TAT-/saline = 12, TAT+/saline = 13, TAT-/methamphetamine = 8, and TAT+/methamphetamine = 
10). 
 
2.3 Methamphetamine regimen 
The methamphetamine binge regimen was previously developed in our laboratory to mimic 
human binge use parameters [22]. The binge consisted of subcutaneous injections of saline or 
methamphetamine (methamphetamine hydrochloride; Sigma, St. Louis, MO, USA; reported as base 
concentration) for four ‘cycles’ of 4 days (four injections/day) with 3 days between cycles (Table 
1). The first cycle featured one week of dose-escalation followed by three repeated identical cycles 
of methamphetamine exposure. These 2-4 cycles consisted of a two-day dose-escalation (3-5 
mg/kg) followed by two days of high dosing (6 mg/kg). Saline and methamphetamine were 
administered at a volume of 5 ml/kg. 
<<<<Insert Table 1>>>> 
Table 1. Methamphetamine binge regimen 
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Cycle 1  2  3  4 
Day 1 2 3 4  9 10 11 12  16 17 18 19  23 24 25 26 
12:00 1 3 5 6  3 5 6 6  3 5 6 6  3 5 6 6 
14:00 1 3 5 6  3 5 6 6  3 5 6 6  3 5 6 6 
16:00 2 4 5 6  4 5 6 6  4 5 6 6  4 5 6 6 
18:00 2 4 5 6  4 5 6 6  4 5 6 6  4 5 6 6 
Methamphetamine doses are reported as base concentration (mg/kg). 
<<<<End Table 1>>>> 
2.4 Visual discrimination task 
2.4.1 Discrimination training 
Visual discrimination training and testing were conducted in twelve Plexiglas operant chambers 
(model ENV-307A, Med Associates Inc., St. Albans, VT, USA), each enclosed in a sound-
attenuating cubicle. The task consisted of 2 continuous reinforcement (CRF) training stages 
followed by the visual discrimination test phase. During the first CRF stage, a single lever was 
presented (left or right, chosen at random). A single lever press resulted in the delivery of a single 
food reward (20 mg Sucrose pellet, TestDiet, IN, USA). The criterion to progress to the next stage 
was >30 lever presses over three days. The second CRF stage was identical, except the lever 
retracted after each press. Following a nose poke in the reward receptacle (15 s hold), a 5 s delay 
was initiated before the lever was extended for the next trial. The criterion to progress to the next 
stage was >40 lever presses with <30% omissions in two of three days. For the visual 
discrimination task, both levers were extended and one of the stimulus lights above the lever was 
illuminated. The mouse was required to press the lever with the associated stimulus light 
illuminated. An incorrect response or failure to respond to either the sample or choice levers during 
the 20 s limited hold (i.e., an omission) resulted in a time out period (house lights on) of 5 s. Correct 
responses were calculated as a percentage of the total trials (not including omissions). The criterion 
to complete visual discrimination and progress to the strategy switch phase was >70% correct trials 
and <30% omissions over three days. Mice were given 60 trials per test session. 
 
2.4.2 Strategy switch 
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Once criteria were met for visual discrimination stage, mice continued onto strategy switch 
testing. All the parameters for testing remained the same as for the visual discrimination test but the 
reward contingencies were changed. Rather than the stimulus light predicting the rewarded lever, 
the spatial location of the lever (left or right) was the relevant reward contingency. The criterion to 
complete testing for strategy shift and progress to reversal learning testing was >70% correct trials 
and <30% omissions over three days. 
 
2.4.3 Spatial reversal learning 
Once criteria were met for the strategy switch stage, mice continued onto reversal learning 
testing. All the parameters remained the same as for the strategy switch test but the reward 
contingencies were changed. For mice where the left lever had previously predicted the reward, the 
right lever was now the correct contingency, and vice versa where the left lever had previously 
predicted the reward. The criterion for completion of reversal learning testing was >70% correct 
trials and <30% omissions over three days. 
 
2.4.4 Behavioral measures 
Behavioral measures included the amount of trials (total, correct and error trials) to reach 
criterion. Latency measures including the amount of time (ms) the animals took to respond and to 
collect the food reward were also recorded. The specific strategies used were also recorded 
including win-stay and lose-shift. That is, following a rewarded trial, a win-stay event was recorded 
if a subject made a response at the same lever. Conversely, following an incorrect response, a lose-
shift event was recorded if a subject made a response at the opposite lever.  
Additional measures were obtained for reversal learning. Specifically, the number of 
perseverative errors, defined as the total number of responses on the previously rewarded lever until 
a correct response was recorded. Further, the number of trials was broken down into early and late 
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learning phases [30]. To define early vs late phase learning, each session was split into blocks of 20 
trials. Once mice reached >50% correct responses in a given block, this and all subsequent blocks 
were considered late phase learning.    
 
2.5 Dopamine transporter quantification 
Briefly, as previously described [31], mouse hemibrain tissue sections were deparaffinized using 
xylene followed by rehydration in serial ethanol and water solutions. Next, tissue sections were 
treated for 30 min with 3% hydrogen peroxide/phosphate-buffered saline (PBS) and then incubated 
for 30 min with 2.5% normal serum, corresponding to the host species for the secondary antibody. 
Tissue sections were then incubated with anti-DAT (Santa Cruz Biotechnology, Dallas, TX; Cat# 
sc-32258; 1:100 in PBS) for 2 h at room temperature in a hydration box. Subsequently, tissue 
sections were washed with 0.1% Tween 20/PBS, before 30 min incubation with horse anti-rabbit 
IgG peroxidase-polymer secondary antibody (ImmPRESS, Vector Laboratories, Burlingame, CA, 
USA). After the tissues were washed with 0.1% Tween 20/PBS, the signals were developed with 
diaminobenzidine (ImmPACT DAB peroxidase substrate, Vector Laboratories) for 5 min. The 
immunostained sections were then dehydrated via serial ethanol and water solutions, de-waxed with 
xylene, and mounted using Cytoseal 60 (ThermoScientific). For the negative control, the primary 
antibody was omitted.  
Subsequently, immunostained sections were scanned using a microscope slide scanner (Aperio 
ScanScope GL, Leica Biosystems, Buffalo Grove, IL, USA) equipped with a 20× objective lens 
(yielding the resolution of 0.5 µm per pixel). Assessment of levels of DAT immunoreactivity was 
performed using the Aperio ImageScope software. For each case a total of three sections (5 images 
per section) were analyzed to estimate the average optical density of immunolabelled cells per unit 
area (mm2). Corrected optical density was calculated by subtracting the background optical density 
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of the negative control (obtained from tissue sections immunostained in the absence of primary 
antibody) from the optical density of the immunostained sections.  
 
2.6 Statistical analyses 
All analyses were performed with IBM SPSS Statistics 20 (Armonk, NY, USA). Data were 
analyzed using analysis of variance (ANOVA), with TAT and Methamphetamine as the between-
subject factors. Repeated-measures ANOVAs were used when within-subject factors were present. 
Data not meeting the assumption of homogeneity of variance were analyzed using Greenhouse-
Geiser adjusted degrees of freedom. When appropriate, post hoc comparisons were performed using 
Least Significant Difference (LSD) analyses. Perseverative errors were analyzed non-parametrically 
using a Kruskal-Wallis ANOVA. Results are expressed as mean ± SEM. Differences were 
considered statistically significant at p<0.05. 
 
3. Results 
3.1 Visual discrimination 
For the trials required to reach criterion, there were significant interactions of Methamphetamine 
x TAT for total trials (Fig 1A; F1,28=4.6, p<0.05) and correct trials (Fig 1B; F1,28=6.1, p<0.05). 
There was also a trend towards an interaction of Methamphetamine x TAT for error trials (Fig 1C; 
F1,28=3.1, p<0.1 NS). TAT expression and methamphetamine exposure alone, but not in 
combination, improved visual discrimination learning as demonstrated by a significant decrease in 
the total and correct trials to reach criterion. There was also a trend (p<0.1) for combined TAT 
expression and methamphetamine exposure to decrease the number of correct trials to reach 
criterion (Fig 1B). 
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There were no significant effects or interactions of TAT or Methamphetamine on the response 
latency (Fig S1A-C) or win-stay/lose-shift strategies used during visual discrimination learning (Fig 
S2A). 
 
3.2 Strategy Shift 
Neither TAT expression nor methamphetamine exposure significantly altered the total trials (Fig 
S3A), correct trials (Fig S3B) and error trials (Fig S3C) to reach criterion. There were also no 
significant effects or interactions of TAT or Methamphetamine on the response latency (Fig S1D-F) 
or win-stay/lose-shift strategies used during the strategy switch (Fig S2B). 
 
3.3 Spatial reversal learning 
Neither TAT expression nor methamphetamine exposure significantly altered the total trials (Fig 
S3D), correct trials (Fig S3E) and error trials (Fig S3F) to reach criterion. There were no significant 
main effects or interactions of TAT or Methamphetamine on the response latency (Fig S1G-I) or 
win-stay/lose-shift strategies used during the strategy switch (Fig S2C). However, there was a 
significant difference between the groups on the number of perseverations (Fig 2; H(3)=8.5, 
p<0.05). The control group showed the lowest level of perseverations, followed by the 
methamphetamine exposed group and the TAT-expressing group, with the greatest level of 
perseverative errors in the methamphetamine exposed, TAT-expressing group. Post hoc tests 
confirmed that the methamphetamine exposed, TAT-expressing group made significantly more 
perseverative errors than control mice (p < 0.05).  
 
Reversal learning features two distinct phases of learning [30]: an early phase (<50% correct 
responses) whereby the animal must learn to disassociate the prior reward contingencies, and a late 
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phase (>50% correct responses) whereby the animal must learn the new associations. The different 
phases can be independently altered after a variety of manipulations [30]. Compared with the late 
phase, the early phase featured less total (Fig 3A; F1,28=71.8, p<0.001) and correct trials (Fig 3B; 
F1,28=383.6, p<0.001) but more errors trials (Fig 3C; F1,28=17.4, p<0.001). Moreover, there was a 
significant interaction of Phase x Methamphetamine x TAT for error trials (F1,28=4.6, p<0.05) and a 
similar trend for total trials (F1,28=3.4, p<0.1 NS). TAT expression tended to decrease early phase 
errors and increase late phase errors (Fig 3C) compared with controls, methamphetamine exposure 
or combined TAT expression and methamphetamine exposure. A similar pattern was observed for 
total trials during early and late phase learning (Fig 3A). There were no significant effects or 
interactions of TAT or Methamphetamine during early or late phase learning for response latency 
(Fig S4A,B) or win-stay/lose-shift strategies (Fig S4C,D). 
 
3.4 Dopamine transporter expression 
In the caudate putamen, there was a significant interaction of Methamphetamine x TAT for 
dopamine transporter expression (F1,35=5.2, p<0.05). TAT expression significantly elevated DAT 
levels compared with controls, methamphetamine exposure and combined TAT expression and 
methamphetamine exposure (Fig 4A). There were no significant effects or interactions of TAT or 
Methamphetamine on dopamine transporter expression in the nucleus accumbens (Fig 4B), 
substantia nigra (Fig 4C) or ventral tegmental area (Fig 4D).  
 
4. Discussion 
The results show a complex pattern of outcomes after TAT expression and/or methamphetamine 
exposure. That is, TAT expression and methamphetamine exposure both independently improved 
visual discrimination learning. TAT expression improved early phase reversal learning, at the 
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expense of late phase reversal learning. TAT expression was also associated with increased 
dopamine transporter levels in the caudate putamen. Surprisingly, the combination of TAT 
expression and methamphetamine exposure did not induce significant learning deficits, but did 
increase perseverations at the initiation of reversal learning suggesting slight impairments in 
executive function. Thus, TAT expression showed subtle effects on learning that may be due to 
alterations in dopaminergic function, but these effects are not summative or synergistic with those 
of methamphetamine.  
Contrary to our expectations, TAT expression and methamphetamine exposure improved 
learning in a visual discrimination task, decreasing the total and correct trials to reach criterion. 
HIV-associated proteins such as gp120 [32], as well as methamphetamine exposure [33], have been 
shown to alter hypothalamic-pituitary-adrenal axis function, which may alter the motivation toward 
food rewards in operant behavioural tasks. However, this is unlikely as the improvement observed 
in the present study was not associated with differences in response latency or the strategies used 
during the task. Although a similar pattern was observed for error trials, the greater magnitude and 
larger effect on the correct trials required would suggest that this outcome may be attributed to an 
increased sensitivity to positive feedback. Rats previously exposed to methamphetamine show an 
increased sensitivity to, and reliance on, positive feedback during discrimination tasks [34]. There is 
also evidence that HIV-positive individuals direct more attention towards reward-associated 
information [35]. Thus, both TAT and methamphetamine exposure can increase the perceived 
relevance of positive feedback, which may explain the present findings. Reinforcement learning is 
heavily associated with dopamine function in mesolimbic projections [36]. We have shown that this 
regimen of methamphetamine exposure induces a persistent decrease in dopamine within the 
nucleus accumbens [22] and that TAT expression also tends to decrease dopamine in the nucleus 
accumbens [13]. Combined TAT expression and methamphetamine exposure tended to show the 
same pattern of improvement; however, this effect was not significant. The effects of dopamine 
levels on cognitive function has a well-established inverted-U-shaped relationship [37], with 
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optimal levels of dopamine required for peak performance (i.e, too much or too little dopamine can 
lead to impaired performance). Thus, it is possible that combined effects of TAT expression and 
methamphetamine exposure on dopamine systems are too large, and performance gains are no 
longer evident. 
TAT expression and methamphetamine exposure induced a complex pattern of effects on 
reversal learning in the present study. Specifically, combined TAT expression and 
methamphetamine exposure increased the level of perseverative responses at the initiation of 
reversal learning. The orbitofrontal cortex and caudate putamen are critical for reversal learning 
[38-40]. The methamphetamine regimen used in the current study led to persistently increased 
dopamine levels in the orbitofrontal cortex and decreased dopamine levels in the caudate putamen 
[22]. Alterations in the neurochemistry of these key regions, combined with TAT expression, could 
explain the increase in perseverative errors observed after combined TAT expression and 
methamphetamine exposure.  
In contrast, TAT expression alone improved early phase reversal learning at the expense of late 
phase reversal learning. Given this effect was associated with selectively increased dopamine 
transporter levels in the caudate putamen of this group, it is tempting to conclude the two are 
associated. However, it is likely more complex as differing factors appear to mediate early and late 
phase reversal learning. For example, selective improvements in early phase reversal learning have 
been observed after increasing serotonin levels in the brain [30]. The selectivity of serotonin 
alterations to early phase reversal learning suggests that early and late phase reversal learning may 
be independent processes. TAT expression has been shown to increase serotonin levels in the 
nucleus accumbens [13] suggesting this may be a potential mechanism for the observed early phase 
improvements. However, whether cortical serotonin levels are altered is not known and how 
influential this may be in HIV infection remains to be determined. Most evidence suggests that 
serotonin level/function is decreased after HIV infection. For example, polymorphisms that reduce 
serotonin function impair cognitive performance in HIV-positive subjects [41] and Simian 
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Immunodeficiency Virus infection in Macaques decreases serotonin levels [42]. This provides 
further evidence that the global effects of HIV disease are the result of multiple factors in 
combination and individual proteins/responses represent only one contributing factor in the 
symptom profile of HIV disease. In contrast to early phase learning, the caudate putamen is crucial 
for establishing and maintaining the new rule in late phase learning. For example, lesions of the 
medial caudate putamen impair reversal learning in rats by increasing the number of errors made 
when learning and maintaining the new rule [39]. Thus, alterations in dopamine signalling, due to 
increased dopamine transporter levels in the caudate putamen, may have selectively impaired late 
phase learning in TAT-expressing mice. This would be consistent with our prior work, whereby 
cessation of TAT protein expression was associated with recovery of dopamine indices and 
improvements in late phase reversal learning [12, 13].  
No significant effects of TAT expression and methamphetamine exposure were observed on the 
strategy-switch phase of testing. The prefrontal cortex is critical for shifting from one rule or 
strategy to another [38-40] so this would suggest that prefrontal cortex function is not impaired 
under the current experimental conditions.  
In conclusion, both TAT expression and methamphetamine exposure may improve associative 
learning under certain experimental conditions by enhancing the response to positive feedback. 
However, an over-emphasis on positive feedback would not be beneficial in more challenging and 
less predictable real-world situations i.e., gambling. Furthermore, an increased drive for positive 
feedback due to TAT expression may make it more difficult for HIV-infected subjects, who are 
dependent, to abstain from using methamphetamine. These results highlight the complexity of 
modelling and understanding HIV disease and methamphetamine abuse. The HIV-associated TAT 
protein likely affects a range of factors, with some potentially improving function under certain 
conditions. 
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FIGURE LEGENDS 
Fig 1. Visual discrimination learning. 
Total (A), correct (B) and error (C) trials to reach criterion on the visual discrimination task in 
TAT-expressing (TAT+) and/or methamphetamine-exposed (METH+) mice. Both TAT-expressing 
(TAT+/METH-) and methamphetamine-exposed (TAT-/METH+) mice required less trials to reach 
criterion than control (TAT-/METH-) mice. This effect was most evident in the total (A; 
Methamphetamine x TAT [F1,28=4.6, p<0.05]) and correct (B; Methamphetamine x TAT [F1,28=6.1, 
p<0.05]) trials required. A similar but non-significant trend was also observed for the number of 
errors (C; Methamphetamine x TAT [F1,28=3.1, p<0.1 NS]). Data are expressed as mean ± SEM. 
*p 
< 0.05 compared to TAT-/METH-. 
 
Fig 2. Perseverative errors during reversal learning 
Perseverative errors at the initial reversal of reward contingencies in TAT-expressing (TAT+) 
and/or methamphetamine exposed (METH+) mice. TAT+/METH+ mice made significantly more 
perseverative errors compared with the control (TAT-/METH-) group (H(3)=8.5, p<0.05). Data are 
expressed are mean ± SEM. *p < 0.05. 
 
Fig 3. Early (<50%) and late phase (>50%) reversal learning 
Total (A), correct (B) and error (C) trials to reach criterion during the early (<50%) and late phases 
(>50%) of reversal learning in TAT-expressing (TAT+) and/or methamphetamine exposed 
(METH+) mice. A significant decrease in error trials was observed during the late phase compared 
with the early phase of learning in all groups except for the TAT+/METH- mice (C; Phase x 
Methamphetamine x TAT [F1,28=4.6, p<0.05]). TAT+/METH- mice tended to make less early phase 
errors and more late phase errors compared with the other groups. Data are expressed as mean ± 
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SEM. *** p <0.001. # p <0.05, ### p <0.001 when comparing <50% with >50% learning phases 
within group. 
 
Fig 4. Dopamine transporter expression 
Relative dopamine transporter pixel intensity in the caudate putamen (A), nucleus accumbens (B), 
substantia nigra (C) and ventral tegmental area (D) in TAT-expressing (TAT+) and/or 
methamphetamine exposed (METH+) mice. TAT+/METH- mice had significantly greater 
dopamine transporter expression in the caudate putamen compared with all other groups (A; 
Methamphetamine x TAT [F1,35=5.2, p<0.05]). Data are expressed as mean ± SEM. * p <0.05, ** p 
<0.01. 
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